Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06605625 · ClinicalTrials.gov registry record
Vaccine Responses in Cancer
A clinical trial of Viral Vaccines, sponsored by Abramson Cancer Center at Penn Medicine.
- Active
- Registry status
- 250
- Enrollment target
- 1
- Study location
NCT06605625: Active study of Viral Vaccines, sponsored by Abramson Cancer Center at Penn Medicine.
NCT06605625 is a study of Viral Vaccines that is active but no longer recruiting, run by Abramson Cancer Center at Penn Medicine. The registered enrollment target is 250 participants. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06605625, a study of Viral Vaccines, is active but no longer recruiting, sponsored by Abramson Cancer Center at Penn Medicine.
- ACTIVE NOT RECRUITING
- Registry status
- 250 participants
- Enrollment target
- 1
- Study location
Study Summary
The investigators are conducting a prospective unblinded study of individuals diagnosed with cancer who will receive one or more of the following: influenza, SARS-CoV2 and shingles.
Primary Outcome
The neutralizing antibody titer will be assessed by measurement of the hemagglutinin-inhibition titer before and after influenza vaccination in order to determine the seroconversion rate. The late blood draw may occur between days 45-90 following vaccination.
Conditions Studied
Interventions
- BIOLOGICAL Influenza vaccination
- BIOLOGICAL SARS-CoV-2 vaccine
- BIOLOGICAL Zoster Vaccine Recombinant
Study Locations (1)
Pennsylvania
- University of Pennsylvania - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 250 participants |
| Start Date | 2022-11-04 |
| Est. Completion | 2028-10 |
What the registry record for NCT06605625 still lists
NCT06605625 is an observational study that tracks outcomes without assigning an intervention. The registered 250 participants enrollment target is mid-sized for trials with a published cap.
The record links to 1 condition, with Viral Vaccines appearing as the primary indexed condition, and to 3 interventions - of which Influenza vaccination is the first listed.
NCT06605625 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT06605625 about?
NCT06605625 is a clinical study titled "Vaccine Responses in Cancer". The investigators are conducting a prospective unblinded study of individuals diagnosed with cancer who will receive one or more of the following: influenza, SARS-CoV2 and shingles.
What is the current status of trial NCT06605625?
This trial is currently active not recruiting. The enrollment target is 250 participants. The study started on 2022-11-04. Estimated completion is 2028-10.
What conditions does trial NCT06605625 study?
This clinical trial studies the following conditions: Viral Vaccines.
What interventions are being tested in trial NCT06605625?
The interventions under investigation include: Influenza vaccination (BIOLOGICAL), SARS-CoV-2 vaccine (BIOLOGICAL), Zoster Vaccine Recombinant (BIOLOGICAL).
Who is sponsoring clinical trial NCT06605625?
This trial is sponsored by Abramson Cancer Center at Penn Medicine, which has 402 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06605625 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Viral Vaccines
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00483249 · 250 participants · NA
Endovascular Exclusion of Thoracoabdominal and/or Paravisceral Abdominal Aortic Aneurysm
- NCT00777712 · 250 participants
Mechanisms Underlying Impaired Diabetic Wound Healing
- NCT01451502 · 250 participants · NA
Infusion of Cell Populations From Unlicensed Umbilical Cord Blood Units
- NCT01771718 · 250 participants
Pilot Study on In-vivo Non-invasive Skin Imaging Using Multiphoton Microscopy
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI